Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has named two new executive team members. The company has named Dr. Amir Inamdar as the chief medical officer for its European operations and Dr. Geoff Varty as the new head of research & development. In addition, the company has made some internal promotions, naming Lori Challenger as chief compliance, ethics & administrative officer and Robert Mino as general counsel. A trained psychiatrist and pharmaceutical physician with more than two decades of clinical and drug-development experience, Inamdar has deep expertise in progressing numerous drugs from preclinical development through to early phase clinical trials, including designing and successfully delivering proof-of-concept studies. Varty has established a reputation as a highly experienced neuroscientist and drug discoverer with a track record of progressing novel molecular entities into clinical trials, and ultimately, to the patient. In addition, Cybin announced that it is partnering with ROK Consulting Inc., a leading investor communications and public relations company. ROK will assist Cybin in strenthening its market awareness, communications strategy, and engagement with leading financial and institutional market participants.
To view the full press release, visit https://ibn.fm/sT4QY
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
